LOADING
Tag: AbbVies
Head-to-head, it’s AbbVie’s Rinvoq over Regeneron’s Dupixent
April 26, 2024
For the second time in four years, AbbVie’s Rinvoq (upadacitinib) has shown superior efficacy to Regeneron and Sanofi’s powerhouse Dupixent (dupilumab) in a head-to-head study in patients with atopic dermatitis (AD). In the LEVEL UP trial testing patients age 12 and older with moderate-to-severe AD who had an inadequate response to systemic therapy, 20% of […]
chat_bubble0 Comment
visibility220 Views
NICE recommends AbbVie’s Rinvoq for atopic dermatitis
June 29, 2022
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Document recommending Rinvoq (upadacitinib), from US drugmaker AbbVie (NYSE: ABBV), as a treatment of moderate to severe atopic dermatitis (AD) for adults and young people aged 12 and over, if the disease has not responded to at least […]
chat_bubble0 Comment
visibility388 Views